Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
about
Calcium-activated-calcineurin reduces the In vitro and In vivo sensitivity of fluconazole to Candida albicans via Rta2pAntifungal Therapy: New Advances in the Understanding and Treatment of MycosisCryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis.Resistance to antifungals that target CYP51.Drug strategies targeting CYP51 in neglected tropical diseasesCryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistanceThe Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.Cryptococcus neoformans Yop1 , an endoplasmic reticulum curvature-stabilizing protein, participates with Sey1 in influencing fluconazole-induced disomy formationCryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylaseRetrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.Identification of QTLs Associated with Virulence Related Traits and Drug Resistance in Cryptococcus neoformans.Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatmentCandida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications.Update on mechanisms of azole resistance in Mycosphaerella graminicola and implications for future control.New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.Mechanisms of Antifungal Drug Resistance.Analysis of sphingolipids, sterols and phospholipids in human pathogenic Cryptococcus strains.Voriconazole is cytotoxic at locally delivered concentrations: a pilot study.A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.An overview about the medical use of antifungals in Portugal in the last years.In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.Update on Antifungal Drug Resistance.Assessing the Risk for Resistance and Elucidating the Genetics of Colletotrichum truncatum That Is Only Sensitive to Some DMI Fungicides.Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase.Environmental triazole induces cross-resistance to clinical drugs and affects morphophysiology and virulence of Cryptococcus gattii and C. neoformans.Role of three Cryptococcus neoformans and C. gattii efflux pump coding genes in response to drug treatment.ERG11 mutations and upregulation in clinical itraconazole-resistant isolates of Candida krusei.Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans.Antifungal Susceptibility Testing of Candida and Cryptococcus Species and Mechanisms of Resistance: Implications for Clinical LaboratoriesResistance to the Plant Defensin NaD1 Features Modifications to the Cell Wall and Osmo-Regulation Pathways of Yeast
P2860
Q28484616-7B4FF200-6428-4F3C-8E7B-ACB9B592424DQ28818603-A72D678F-48A6-4B99-8187-ABE0C133DAAFQ33790656-4ACAB1AA-46D3-4A70-A09F-C30920B5B34AQ34276700-72681AAD-BF13-4F67-AAD5-65E159EC729AQ34622554-CD509E98-3A07-42B7-996B-3873070F24F2Q34943653-6AF3E423-9BE8-4CF6-B819-D5D40B92863AQ36012849-798301F3-6960-4727-A439-ACC125DD7636Q36319731-638738F6-D883-487D-B633-2F3A1024926EQ36364064-F7D7AC28-F3A7-4FF0-B13B-4FC99F7D6AFCQ36445833-39CBA8B4-56CA-4322-A1B6-EC5C9859DEE7Q36644733-B3ED804D-B388-4F55-9EAD-481AAE7A2CC8Q36910544-D782FDD6-BCD0-4607-A77D-F7E2001C3D95Q37091636-63D6FD78-C0D1-4E58-AC4C-AABE5F20A3BEQ37242018-DC07C20F-B5D9-453E-94F0-14A1A77DF2EEQ37263749-C4D847C2-4BC3-4230-981E-741FA97EAE79Q37263791-55D49B00-01D4-4746-A2A2-99DBC6334515Q38021430-25AAFB8B-7EF6-4855-8A85-621907B112B1Q38024052-7481ED85-6EB2-4A37-BB6F-2424830C6BD7Q38266675-4D2DC815-9035-4A5C-A6D8-D9676DE17EF4Q38623199-3AF6D2EC-0A06-4138-826B-9F152E6548B9Q39189482-847D50D4-52C1-4B04-90E7-01AFE9E02611Q39530506-40AC4EC6-7AC6-4673-A4CD-E4A8CFA5C647Q40538476-D1A242C5-3DE8-4E1F-8EC4-3140B8F156D1Q40796297-6B0F3DEC-5294-4DD1-A572-161239059715Q40851096-312F0B83-285B-4706-BEA5-DB8DB32945ACQ41135029-E763758C-2ABE-4E07-BA29-33980F833C3FQ41889763-488E7363-5647-4612-87BE-67BFDD9204CFQ42110028-7EA074E7-779E-4A46-88DE-BC998788FD97Q46256758-B958B5DD-FA39-4551-A61D-060940EC21BBQ46267535-E5972706-F5D3-4593-BF78-D523CF8F5373Q49598890-3A7591B9-31EA-4EDF-A7A4-78834FCFC3C5Q51512831-93956F2E-3C66-4E1E-9D83-05AAA88DB57DQ52629897-AE1C1C8E-7E78-423C-8A53-3FC4C5F841DCQ57745988-5A12AFAD-0D1D-401A-A6E4-3FE924E44153Q58199146-CEFEDC63-C42F-4EC8-BF84-AE9E2FF22E8F
P2860
Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Identification of a Cryptococc ...... and itraconazole/posaconazole.
@ast
Identification of a Cryptococc ...... and itraconazole/posaconazole.
@en
type
label
Identification of a Cryptococc ...... and itraconazole/posaconazole.
@ast
Identification of a Cryptococc ...... and itraconazole/posaconazole.
@en
prefLabel
Identification of a Cryptococc ...... and itraconazole/posaconazole.
@ast
Identification of a Cryptococc ...... and itraconazole/posaconazole.
@en
P2093
P2860
P356
P1476
Identification of a Cryptococc ...... and itraconazole/posaconazole.
@en
P2093
Edward Sionov
H Martin Garraffo
Kyung J Kwon-Chung
Mahmoud A Ghannoum
Michael A Dolan
Yun C Chang
P2860
P304
P356
10.1128/AAC.05502-11
P407
P577
2011-12-12T00:00:00Z